Memorial Sloan Kettering Cancer Center‘s patent involves using biomarkers to predict the effectiveness of CDK4 inhibitors in treating certain cancers. The method includes detecting CDH18 protein expression patterns in cancer cells to determine suitability for treatment. This innovation could lead to personalized cancer therapies for liposarcoma, glioma, lung, and breast cancers. GlobalData’s report on Memorial Sloan Kettering Cancer Center gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

According to GlobalData’s company profile on Memorial Sloan Kettering Cancer Center, was a key innovation area identified from patents. Memorial Sloan Kettering Cancer Center's grant share as of February 2024 was 33%. Grant share is based on the ratio of number of grants to total number of patents.

Selecting cancer patients for cdk4 inhibitor treatment

Source: United States Patent and Trademark Office (USPTO). Credit: Memorial Sloan Kettering Cancer Center

A recently granted patent (Publication Number: US11921116B2) outlines a method for selecting cancer patients for treatment with a CDK4 inhibitor. The method involves detecting the CDH18 protein expression pattern within cancer cells obtained from patients and selecting those where the protein is localized to foci within the cells. The CDK4 inhibitor is then administered to patients with liposarcoma, glioma, non-small cell lung cancer, or breast cancer. The detection of CDH18 can be done through immunofluorescence, and the treatment extends to patients who have already received CDK4 inhibitor therapy.

Furthermore, the patent details a method for treating cancer in patients who have undergone CDK4 inhibitor therapy. Similar to the previous method, CDH18 protein expression pattern is detected in cancer cells, patients with the protein localized to foci are selected, and a CDK4 inhibitor is administered. The cancers targeted for treatment remain the same - liposarcoma, glioma, non-small cell lung cancer, and breast cancer. The CDK4 inhibitors mentioned in the patent include palbociclib, ribociclib, abemaciclib, PD0332991, P1446A-05, trilaciclib, flavopiridol hydrochloride, CDK4 antisense oligonucleotide, CDK4 shRNA, or CDK4 siRNA. This patent provides a structured approach to selecting and treating cancer patients with CDK4 inhibitors based on the expression pattern of the CDH18 protein within cancer cells.

To know more about GlobalData’s detailed insights on Memorial Sloan Kettering Cancer Center, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies